title: Changes in sleep electroencephalogram and nocturnal hormone secretion after administration of the antidyskinetic agent sarizotan in healthy young male volunteers.
abstract: BACKGROUND
  Sarizotan is a 5-HT(1A) agonist with high affinity to D(3) and D(4) receptors. In animal experiments, the drug shows a strong anti-cataleptic effect and suppresses effectively dyskinesias in animal models of L: -dopa-induced dyskinesia and of tardive dyskinesia. Data from an open pilot study in patients with Parkinson's disease show clear indication of a treatment effect against L: -dopa-induced dyskinesia.
  
  
  OBJECTIVE
  CNS-active drugs are known to modulate sleep electroencephalogram (EEG) and sleep-related hormone secretion. 5-HT(1A) agonists suppress rapid-eye movement (REM) sleep and enhance the secretion of ACTH, cortisol, prolactin and growth hormone (GH) at daytime. We hypothesised that sarizotan shares these effects. Furthermore, we were interested in the influence of sarizotan on leptin, which participates in the regulation of the energy balance and is enhanced after various psychoactive drugs.
  
  
  METHODS
  Ten healthy male subjects were investigated twice in a double-blind, placebo-controlled crossover design. Sleep EEG and nocturnal hormone secretion of ACTH, cortisol, prolactin, GH and leptin were examined after oral administration of either placebo or 20 mg of sarizotan at night.
  
  
  RESULTS
  After administration of sarizotan, a significant reduction of REM sleep and total sleep time in conventional sleep EEG and a significant reduction of sigma- and theta-power in spectral analysis were observed. The main effect on nocturnal hormone secretion was a significant elevation of prolactin and of ACTH in the first half of the night.
  
  
  CONCLUSIONS
  While REM sleep was suppressed, the endocrine effects of 20 mg sarizotan at night were weak. Its sleep-endocrine profile is comparable to the effects provoked by selective 5-HT reuptake inhibitors.
authors.affiliation: Department of Psychiatry, Max Planck Institute of Psychiatry, Kraepelinstrasse 2-10, 80804, Munich, Germany.
authors.forename: Heike E
authors.initials: HE
authors.lastname: Kuenzel
authors.forename: Axel
authors.initials: A
authors.lastname: Steiger
authors.forename: Katja
authors.initials: K
authors.lastname: Held
authors.forename: Irina A
authors.initials: IA
authors.lastname: Antonijevic
authors.forename: Ralf-Michael
authors.initials: RM
authors.lastname: Frieboes
authors.forename: Harald
authors.initials: H
authors.lastname: Murck
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000097:blood; D000328:Adult; D004311:Double-Blind Method; D004569:Electroencephalography / Q000187:drug effects*; D006728:Hormones / Q000097:blood*; D019382:Human Growth Hormone / Q000097:blood; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D020738:Leptin / Q000097:blood; D008297:Male; D009930:Organic Chemicals / Q000494:pharmacology; D011388:Prolactin / Q000097:blood; D017366:Serotonin Receptor Agonists / Q000494:pharmacology*; D012890:Sleep / Q000502:physiology*
chemical_list: D006728:Hormones; D020738:Leptin; D009930:Organic Chemicals; D017366:Serotonin Receptor Agonists; D019382:Human Growth Hormone; C443959:sarizotan; D000324:Adrenocorticotropic Hormone; D011388:Prolactin; D006854:Hydrocortisone
references.citation: Clin Neuropharmacol. 2004 Mar-Apr;27(2):58-62
references.pmid: 15252265
references.citation: J Neural Transm (Vienna). 1996;103(1-2):77-88
references.pmid: 9026379
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 1993 Jan;17(1):125-37
references.pmid: 8416599
references.citation: Brain Res. 1992 Sep 4;589(2):253-61
references.pmid: 1393593
references.citation: Neuropsychobiology. 2000;42(2):69-81
references.pmid: 10940762
references.citation: Clin Neurophysiol. 2002 Mar;113(3):429-34
references.pmid: 11897543
references.citation: Front Biosci. 2003 May 01;8:s358-76
references.pmid: 12700062
references.citation: Biol Psychiatry. 1998 Jul 1;44(1):21-33
references.pmid: 9646880
references.citation: Psychopharmacology (Berl). 1990;100(4):498-503
references.pmid: 2157231
references.citation: Neurology. 2001 Nov 27;57(10):1829-34
references.pmid: 11723272
references.citation: J Sleep Res. 1992 Sep;1(3):169-175
references.pmid: 10607047
references.citation: Life Sci. 1980 Oct 20;27(16):1435-51
references.pmid: 6160367
references.citation: Life Sci. 2000 Apr 14;66(21):1999-2012
references.pmid: 10823340
references.citation: Adv Neurol. 1996;69:545-50
references.pmid: 8615179
references.citation: Neuropsychopharmacology. 2003 Feb;28(2):348-58
references.pmid: 12589388
references.citation: Neuropsychopharmacology. 2001 Sep;25(3):395-401
references.pmid: 11522467
references.citation: J Neural Transm (Vienna). 2004 Feb;111(2):113-26
references.pmid: 14767715
references.citation: Psychopharmacology (Berl). 2001 May;155(2):187-92
references.pmid: 11401008
references.citation: Neuropharmacology. 2004 Mar;46(4):497-503
references.pmid: 14975673
references.citation: Am J Psychiatry. 1999 Feb;156(2):312-4
references.pmid: 9989571
references.citation: Br J Psychiatry. 2001 Jul;179:59-62
references.pmid: 11435270
references.citation: Psychoneuroendocrinology. 2000 May;25(4):377-88
references.pmid: 10725614
references.citation: Mov Disord. 1990;5(4):280-5
references.pmid: 2259351
references.citation: Pharmacopsychiatry. 2004 Jul;37(4):157-62
references.pmid: 15467971
references.citation: Neuropharmacology. 2003 Dec;45(8):1057-69
references.pmid: 14614949
references.citation: Prog Brain Res. 1986;66:107-16
references.pmid: 2431436
references.citation: Biol Psychiatry. 1990 Oct 1;28(7):620-8
references.pmid: 1977479